India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

USV launches empagliflozin and its combinations for diabetes care in India: Our Bureau, Bengaluru Wednesday, March 19, 2025, 12:40 Hrs [IST] USV, an Indian multinational healthcar ...

The Drug is produced at the USFDA approved facilities of Morepen, which is compliant with global quality standards for ...

Pharmaceutical company Morepen Laboratories Ltd on Monday (March 17) said it has launched a new treatment for Type 2 diabetes, heart failure, and chronic kidney disease. The drug, Empamore, is said to ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

The price of empagliflozin, a commonly prescribed diabetes drug, has been slashed by a staggering 90% in India. This ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

The price of commonly used diabetes drug empagliflozin has been slashed by almost one-tenth, with the entry of its generic ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...